Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1223 Neoplasms 1041 Carcinoma, Non-Small-Cell Lung 755 Prostatic Neoplasms 693 Colorectal Neoplasms 593 Lung Neoplasms 574 Pancreatic Neoplasms 402 Leukemia, Myeloid, Acute 399 Neoplasm Metastasis 387 Multiple Myeloma 374 Ovarian Neoplasms 372 Stomach Neoplasms 317 Carcinoma, Hepatocellular 303 Melanoma 282 Recurrence 281 Brain Neoplasms 281 Squamous Cell Carcinoma of Head and Neck 268 Head and Neck Neoplasms 237 Endometrial Neoplasms 235 Glioblastoma 234 Triple Negative Breast Neoplasms 230 Precursor Cell Lymphoblastic Leukemia-Lymphoma 226 Uterine Cervical Neoplasms 225 Lymphoma 224 Hematologic Neoplasms 200 Sarcoma 199 Urinary Bladder Neoplasms 197 Esophageal Neoplasms 191 Carcinoma, Renal Cell 190 Lymphoma, Non-Hodgkin 176

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Metastatic Urothelial Cancer × 1 year × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡